KANG News Alert Ikang Healthcare Group Inc. (KANG) 17.49 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 1:18 PM

Ikang Healthcare Group Inc. (KANG) 17.49 $KANG

February Starts On A Sour Note
China Stock Research - Seeking Alpha - Mon Feb 02, 9:19AM CST
This weekend, the NBS published both manufacturing and non-manufacturing PMI data which pointed to ongoing headwinds in China's economy. Although there were a few bright spots in the data (SMEs marginally improving, some progress in...
XPP: 73.36 (+0.86), VIPS: 21.80 (+0.36), YY: 63.08 (-0.96), KANG: 17.49 (+0.50), CMCM: 20.20 (+0.10), CHXF: 53.10 (+0.30), YINN: 38.57 (+0.69), MCHI: 52.12 (+0.31), TOUR: 15.09 (+0.02), CCIH: 10.50 (+0.01), YANG: 9.94 (-0.17), TAOM: 3.16 (-0.07), FXP: 38.91 (-0.47), PGJ: 28.89 (+0.28), FCA: 23.21 (+0.38), EHIC: 10.48 (-0.01), WX: 41.53 (+0.45), YAO: 28.18 (+0.30), YXI: 27.30 (unch), CN: 34.87 (+0.34), FXI: 42.98 (+0.27), GXC: 81.15 (+0.54)

iKang to Attend J.P.Morgan Healthcare Conference in San Francisco
GlobeNewswire - Tue Jan 06, 7:00AM CST
iKang Healthcare Group, Inc. ("iKang" or the "Company"

(Nasdaq:KANG), the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, today announced that it will attend the 33 Annual J.P.Morgan Healthcare Conference to be held on January 12 to 15 at the Westin St. Francis Hotel in San Francisco.
KANG: 17.49 (+0.50)

Week In Review: 2014 Pharma IPOs In China - Just 3
ChinaBio Today - at Seeking Alpha - Sun Jan 04, 4:46AM CST
Deals and Financings 2014 was supposed to be a breakout year for China life science IPOs. As the year began, China was all set to resume IPOs after a 15-month moratorium, with a new regulatory system and significant pent-up demand. But, for the...
TPI: 0.54 (+0.01), KANG: 17.49 (+0.50), WX: 41.53 (+0.45)

2014 Chinese IPOs In The U.S. - It's Good To Be Big
China Stock Research - Seeking Alpha - Tue Dec 30, 7:44AM CST
2014 marked a return to strong growth in the number of Chinese companies choosing to IPO in the US, and was also a multi-year high for the amount of money investors poured in (thanks to two mega-deals). In total, there were 14 IPOs in 2014 which...
LEJU: 10.88 (+0.48), WB: 13.30 (-0.17), XNET: 7.93 (+0.23), ZPIN: 16.16 (-0.16), JMEI: 12.67 (+0.31), KANG: 17.49 (+0.50), CMCM: 20.20 (+0.10), TEDU: 11.36 (-0.15), EHIC: 10.48 (-0.01), JD: 26.23 (-0.27), MOMO: 11.02 (-0.47), DSKY: 11.99 (+0.14), TOUR: 15.09 (+0.02), BABA: 89.05 (+1.95)

Geographic Expansion, New Verticals And Secular Tailwinds Make IKang A Solid Long-Term Investment
ONeil Trader - at Seeking Alpha - Tue Dec 16, 9:00AM CST

KANG: 17.49 (+0.50)

iKang Healthcare (KANG) Crumbles: Stock Falls by 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:43AM CST
So make sure to keep a close watch on iKang Healthcare in the near future, and especially on earnings estimates following the recent slump.
KANG: 17.49 (+0.50)

iKang Healthcare Group Second-Quarter Earnings Shows Continued Growth
The Panoramic View - at Seeking Alpha - Mon Dec 01, 7:42PM CST

KANG: 17.49 (+0.50)

iKang Healthcare Group's (KANG) CEO Li Zhang on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 25, 1:00PM CST

KANG: 17.49 (+0.50)

iKang affirms guidance after FQ2 results
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 6:40AM CST

KANG: 17.49 (+0.50)

iKang beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 4:04PM CST

KANG: 17.49 (+0.50)

iKang Announces Unaudited Financial Results for Fiscal Second Quarter Ended September 30, 2014
GlobeNewswire - Mon Nov 24, 4:00PM CST
iKang Healthcare Group, Inc. ("iKang" or the "Company"

(Nasdaq:KANG), the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, today announced its unaudited financial results for the fiscal second quarter ended September 30, 2014.
KANG: 17.49 (+0.50)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 23, 4:35PM CST

QIHU: 60.48 (+1.47), ANW: 14.92 (+0.25), NUAN: 14.26 (+0.20), WDAY: 91.84 (+0.67), KANG: 17.49 (+0.50), CPRT: 38.17 (+0.23), PANW: 135.27 (+2.26), DY: 37.84 (+0.35), BRCD: 12.56 (+0.50), VMEM: 4.12 (unch), ANFI: 8.84 (-0.42)

iKang's Chairman and CEO, Mr. Lee Ligang Zhang Named EY Entrepreneur Of The Year(TM) 2014 National Life Sciences Award Winner
GlobeNewswire - Fri Nov 21, 7:07AM CST
iKang Healthcare Group, Inc. ("iKang" or the "Company"

(Nasdaq:KANG), the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, today announced Mr. Lee Ligang Zhang, the Company's Founder, Chairman and CEO, has been named the EY Entrepreneur Of The Year(TM) 2014 National Life Sciences Award winner.
SBUX: 91.58 (-0.24), KANG: 17.49 (+0.50)

iKang Announces Acquisition of Three Medical Centers in Shenyang
GlobeNewswire - Wed Nov 19, 7:08AM CST
iKang Healthcare Group, Inc. ("iKang" or the "Company"

(Nasdaq:KANG), the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, today announced the acquisition of three medical centers in Shenyang that are franchised from Ciming Checkup Group ("Shenyang Medical Center"

. Upon completion of the acquisition, iKang will operate a network of 53 self-owned medical centers across China.
KANG: 17.49 (+0.50)

iKang reports November 24
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:43AM CST

KANG: 17.49 (+0.50)

iKang Healthcare Group, Inc. Schedules 2014 Unaudited Second Quarter Earnings Release on November 24, 2014
GlobeNewswire - Mon Nov 10, 7:45AM CST
iKang Healthcare Group, Inc. ("iKang" or the "Company"

(Nasdaq:KANG), the largest provider in China's fast growing private preventive healthcare services market in terms of revenue, today announced that it will release its unaudited financial results for the second quarter ended September 30, 2014 on November 24, 2014 after the US market closes.
KANG: 17.49 (+0.50)

5 Stocks Poised for Breakouts
at The Street - Fri Oct 03, 1:22PM CDT
These stocks look ready to break out and trade higher from current levels.
WFM: 56.15 (-0.15), FLL: 1.47 (-0.03), CNAT: 5.92 (+0.10), KANG: 17.49 (+0.50), FUEL: 14.30 (+0.65), ZU: 14.22 (-0.30)

Tarena Is Rare Among Recent IPOs: It's Making Money
at Investor's Business Daily - Wed Sep 03, 4:06PM CDT
The April initial public offering Tarena International is among a small group of recent IPOs with a profitable history. Many IPOs debut with just a promise of profits. Some only recently turned profitable. Others, however, have shown progressively...
GPRO: 45.27 (-0.02), KANG: 17.49 (+0.50), TEDU: 11.36 (-0.15)

iKang Healthcare Slumps: KANG Plunges 13.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:41AM CDT
iKang Healthcare has been witnessing a flat earnings estimate record and its share price has been falling for past one day
AIRM: 45.33 (+0.24), KANG: 17.49 (+0.50), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)

iKang Healthcare Group, Inc. (KANG) Jumps: Stock Surges 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:11AM CDT
iKang Healthcare Group, Inc. (KANG) was a big mover last session, as the company saw its shares rise over 10% on the day.
AIRM: 45.33 (+0.24), KANG: 17.49 (+0.50), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...